Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia

Immunotherapy
Binsah GeorgeNitin Jain

Abstract

Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90-100% of malignant mature B-lymphocyte lineage. The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al. gave the opportunity for heavily pretreated patients with acute lymphoblastic leukemia to go for allogeneic stem cell transplant. Inotuzumab is well-tolerated with the exception of veno-occlusive disease. Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients.

References

Jan 1, 1997·Annual Review of Immunology·T F TedderJ H Kehrl
Jan 9, 2001·Hematology/oncology Clinics of North America·N GökbugetD Messerer
Jan 9, 2001·Hematology/oncology Clinics of North America·R A Larson
Apr 23, 2002·Scandinavian Journal of Immunology·J E Moyron-QuirozL Santos-Argumedo
Mar 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·BinuJoy JohnLouis B Justement
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F DiJosephNitin K Damle
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F DiJosephNitin K Damle
Oct 13, 2006·Blood·Adele K FieldingUNKNOWN Eastern Cooperative Oncology Group
Jul 15, 2009·Immunological Reviews·Lars Nitschke
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anjali AdvaniLuis Fayad
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato BassanAlessandro Rambaldi
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato Bassan, Dieter Hoelzer
Oct 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alejandro D Ricart
Apr 17, 2012·Expert Opinion on Investigational Drugs·Xavier Thomas
Aug 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop KantarjianSusan O'Brien
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farhad RavandiHagop M Kantarjian
Mar 26, 2013·Natural Product Reports·Hans-Peter GerberRobert T Abraham
May 23, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Loretta Sullivan-ChangJoseph M Tuscano
Jul 12, 2013·Leukemia & Lymphoma·Craig A Portell, Anjali S Advani
Jan 7, 2014·Frontiers in Bioscience (Elite Edition)·Nitin JainHagop Kantarjian
Jul 2, 2014·European Journal of Haematology·Caroline Le Jeune, Xavier Thomas
Mar 17, 2015·Expert Opinion on Biological Therapy·Maro OhanianSusan O'Brien
Mar 18, 2015·Nature Reviews. Clinical Oncology·Kathryn G Roberts, Charles G Mullighan

❮ Previous
Next ❯

Citations

Dec 1, 2017·Current Opinion in Pediatrics·Liora M SchultzCrystal Mackall
Jun 21, 2019·Expert Review of Clinical Immunology·Chelsea KotchDavid T Teachey

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
xenografts
ELISA

Clinical Trials Mentioned

NCT01564784

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.